7.05

3.69% -0.27

Pre-market: 7.49 0.44 +6.24%

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $7.05, with a volume of 192.85K. It is down -3.69% in the last 24 hours and down -4.47% over the past month. Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Previous Close:

$7.32

Open:

$7.31

24h Volume:

192.85K

Relative Volume:

0.64

Market Cap:

$280.56M

Revenue:

$68.68M

Net Income/Loss:

$-60.84M

P/E Ratio:

-4.4063

EPS:

-1.6

Net Cash Flow:

$-38.42M

1W Performance:

-5.24%

1M Performance:

-4.47%

6M Performance:

-15.16%

1Y Performance:

-19.70%

1-Day Range:

$6.97

$7.56

1-Week Range:

$6.97

$7.80

52-Week Range:

$5.46

$10.01

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1169)

Industry

Medical Devices (159)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

291

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	7.05	280.56M	68.68M	-60.84M	-38.42M	-1.60
ABT Abbott Laboratories	129.89	225.27B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	95.37	140.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	363.66	138.77B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	92.33	118.39B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	67.95	39.95B	5.72B	4.17B	259.90M	6.97

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Mar 10, 2025

Boral Capital sets Pulmonx stock Buy rating, $17 target - Investing.com India

Mar 10, 2025

Boral Capital sets Pulmonx stock Buy rating, $17 target By Investing.com - Investing.com South Africa

Mar 10, 2025

This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 10, 2025

Mar 06, 2025

Pulmonx corp’s chief commercial officer sells $41,191 in stock - Investing.com India

Mar 06, 2025

Mar 05, 2025

Pulmonx CFO Mehul Joshi sells $102,414 in stock By Investing.com - Investing.com Australia

Mar 05, 2025

Pulmonx Corp CEO Steven Williamson sells $197,699 in stock - Investing.com India

Mar 05, 2025

Pulmonx CFO Mehul Joshi sells $102,414 in stock - Investing.com India

Mar 05, 2025

Pulmonx corp’s chief commercial officer sells $41,191 in stock By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 03, 2025

Can This Medical Device Expert Help EDAP Dominate the $8.5B Prostate Cancer Market? - StockTitan

Mar 03, 2025

Pulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Mar 03, 2025

Mar 01, 2025

Pulmonx director French Glendon E. III sells shares worth $29,625 - MSN

Mar 01, 2025

Feb 24, 2025

Pulmonx director French Glendon E. III sells $459,085 in shares By Investing.com - Investing.com Canada

Feb 24, 2025

Pulmonx director French Glendon E. III sells $459,085 in shares - Investing.com India

Feb 24, 2025

Feb 21, 2025

Pulmonx Corporation shares spike on record-breaking Q4 revenue - Mugglehead

Feb 21, 2025

Stock summary: Pulmonx witnessed weekly surge of 20.43% after fourth-quarter earnings exceed expectations - Business Upturn

Feb 21, 2025

Feb 20, 2025

Top 3 Health Care Stocks You May Want To Dump In February - Benzinga

Feb 20, 2025

Pulmonx Corporation (NASDAQ:LUNG) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 20, 2025

Citi raises Pulmonx stock target following record revenue - Investing.com India

Feb 20, 2025

Citi raises Pulmonx stock target following record revenue By Investing.com - Investing.com Nigeria

Feb 20, 2025